Embryonic Stem Cell Therapy after Cervical Contusion SCI in NHPs

NHP 宫颈挫伤 SCI 后的胚胎干细胞治疗

基本信息

项目摘要

This new application represents a continuation of the California Primate Spinal Cord Research Consortium project on human embryonic stem cell (hESC) derived neural stem cell transplantation; our overarching goal is to understand both basic mechanisms of spinal cord organization and function in non-human primates, and to leverage these and other advances in developing translational human pro-regenerative therapies. We have made considerable progress in the last 5 years and now propose new specific aims that will directly bear on the potential of human neural stem cells (NSCs) to benefit human SCI. Aim 1: Examine Mechanisms Underlying Graft-Related Functional Improvement: Graft Silencing with Inhibitory DREADDs. Work in this aim will establish whether functional recovery observed in non-human primates after grafts of spinalized neural stem cells is related to graft activation of host neural circuits. This knowledge will be important for human translation. Aim 2: Determine Whether 4-AP Improves Anatomical and Functional Outcomes After Neural Stem Cell Grafts There is a vast literature supporting potentially beneficial effects of 4AP in SCI, and 4AP is approved for human use as a conduction-enhancing drug in multiple sclerosis. This aim will determine whether treatment with neural stem cell grafts plus 4AP improves anatomical and functional outcomes. Aim 3: Determine Whether PTEN/SOCS3 Inhibition Improves Host Corticospinal Regeneration and Functional Outcomes. Rodent studies indicate that functional benefits of neural stem cell grafts are mediated by formation of host-to-graft-to-host electrophysiological relays across sites of SCI. These relays require host axon regeneration into grafts. In humans, corticospinal axons are essential for voluntary movement. This aim will determine whether inactivation of PTEN/SOCS3 will enhance corticospinal axon regeneration and improve functional outcomes in primates.
这个新的应用代表了加州灵长类动物脊髓研究的延续

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

JACQUELINE C BRESNAHAN其他文献

JACQUELINE C BRESNAHAN的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('JACQUELINE C BRESNAHAN', 18)}}的其他基金

Translational Outcomes Project: Visualizing Syndromic Information and Outcomes for Neurotrauma (TOP-VISION)
转化结果项目:可视化神经创伤的症状信息和结果 (TOP-VISION)
  • 批准号:
    10408138
  • 财政年份:
    2018
  • 资助金额:
    $ 68.67万
  • 项目类别:
Translational Outcomes Project: Visualizing Syndromic Information and Outcomes for Neurotrauma (TOP-VISION)
转化结果项目:可视化神经创伤的症状信息和结果 (TOP-VISION)
  • 批准号:
    10092617
  • 财政年份:
    2018
  • 资助金额:
    $ 68.67万
  • 项目类别:
FAIR VISION for TOP-NT
TOP-NT 的公平愿景
  • 批准号:
    10407811
  • 财政年份:
    2018
  • 资助金额:
    $ 68.67万
  • 项目类别:
Translational Outcomes Project: Visualizing Syndromic Information and Outcomes for Neurotrauma (TOP-VISION)
转化结果项目:可视化神经创伤的症状信息和结果 (TOP-VISION)
  • 批准号:
    10199067
  • 财政年份:
    2018
  • 资助金额:
    $ 68.67万
  • 项目类别:
Embryonic stem cell therapy after cervical contusion SCI in NHPs
NHP 宫颈挫伤 SCI 后的胚胎干细胞治疗
  • 批准号:
    9472452
  • 财政年份:
    2017
  • 资助金额:
    $ 68.67万
  • 项目类别:
Embryonic stem cell therapy after cervical contusion SCI in NHPs
NHP 宫颈挫伤 SCI 后的胚胎干细胞治疗
  • 批准号:
    10210306
  • 财政年份:
    2017
  • 资助金额:
    $ 68.67万
  • 项目类别:
32nd Annual National Neurotrauma Symposium
第32届全国神经创伤年度研讨会
  • 批准号:
    8785233
  • 财政年份:
    2014
  • 资助金额:
    $ 68.67万
  • 项目类别:
Plasticity and Regeneration in the Primate Spinal Cord
灵长类脊髓的可塑性和再生
  • 批准号:
    8438429
  • 财政年份:
    2011
  • 资助金额:
    $ 68.67万
  • 项目类别:
Plasticity and Regeneration in the Primate Spinal Cord
灵长类脊髓的可塑性和再生
  • 批准号:
    8318074
  • 财政年份:
    2011
  • 资助金额:
    $ 68.67万
  • 项目类别:
Plasticity and Regeneration in the Primate Spinal Cord
灵长类脊髓的可塑性和再生
  • 批准号:
    8640211
  • 财政年份:
    2011
  • 资助金额:
    $ 68.67万
  • 项目类别:

相似国自然基金

Agonist-GPR119-Gs复合物的结构生物学研究
  • 批准号:
    32000851
  • 批准年份:
    2020
  • 资助金额:
    24.0 万元
  • 项目类别:
    青年科学基金项目

相似海外基金

S1PR1 agonistによる脳血液関門制御を介した脳梗塞の新規治療法開発
S1PR1激动剂调节血脑屏障治疗脑梗塞新方法的开发
  • 批准号:
    24K12256
  • 财政年份:
    2024
  • 资助金额:
    $ 68.67万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
AHR agonistによるSLE皮疹の新たな治療薬の開発
使用 AHR 激动剂开发治疗 SLE 皮疹的新疗法
  • 批准号:
    24K19176
  • 财政年份:
    2024
  • 资助金额:
    $ 68.67万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Evaluation of a specific LXR/PPAR agonist for treatment of Alzheimer's disease
特定 LXR/PPAR 激动剂治疗阿尔茨海默病的评估
  • 批准号:
    10578068
  • 财政年份:
    2023
  • 资助金额:
    $ 68.67万
  • 项目类别:
AUGMENTING THE QUALITY AND DURATION OF THE IMMUNE RESPONSE WITH A NOVEL TLR2 AGONIST-ALUMINUM COMBINATION ADJUVANT
使用新型 TLR2 激动剂-铝组合佐剂增强免疫反应的质量和持续时间
  • 批准号:
    10933287
  • 财政年份:
    2023
  • 资助金额:
    $ 68.67万
  • 项目类别:
Targeting breast cancer microenvironment with small molecule agonist of relaxin receptor
用松弛素受体小分子激动剂靶向乳腺癌微环境
  • 批准号:
    10650593
  • 财政年份:
    2023
  • 资助金额:
    $ 68.67万
  • 项目类别:
AMPKa agonist in attenuating CPT1A inhibition and alcoholic chronic pancreatitis
AMPKa 激动剂减轻 CPT1A 抑制和酒精性慢性胰腺炎
  • 批准号:
    10649275
  • 财政年份:
    2023
  • 资助金额:
    $ 68.67万
  • 项目类别:
A randomized double-blind placebo controlled Phase 1 SAD study in male and female healthy volunteers to assess safety, pharmacokinetics, and transient biomarker changes by the ABCA1 agonist CS6253
在男性和女性健康志愿者中进行的一项随机双盲安慰剂对照 1 期 SAD 研究,旨在评估 ABCA1 激动剂 CS6253 的安全性、药代动力学和短暂生物标志物变化
  • 批准号:
    10734158
  • 财政年份:
    2023
  • 资助金额:
    $ 68.67万
  • 项目类别:
Investigating mechanisms underpinning outcomes in people on opioid agonist treatment for OUD: Disentangling sleep and circadian rhythm influences on craving and emotion regulation
研究阿片类激动剂治疗 OUD 患者结果的机制:解开睡眠和昼夜节律对渴望和情绪调节的影响
  • 批准号:
    10784209
  • 财政年份:
    2023
  • 资助金额:
    $ 68.67万
  • 项目类别:
A novel nanobody-based agonist-redirected checkpoint (ARC) molecule, aPD1-Fc-OX40L, for cancer immunotherapy
一种基于纳米抗体的新型激动剂重定向检查点 (ARC) 分子 aPD1-Fc-OX40L,用于癌症免疫治疗
  • 批准号:
    10580259
  • 财政年份:
    2023
  • 资助金额:
    $ 68.67万
  • 项目类别:
Identification and characterization of a plant growth promoter from wild plants: is this a novel plant hormone agonist?
野生植物中植物生长促进剂的鉴定和表征:这是一种新型植物激素激动剂吗?
  • 批准号:
    23K05057
  • 财政年份:
    2023
  • 资助金额:
    $ 68.67万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了